purchase customization

1 Study Coverage
1.1 Radiopharmaceuticals in Nuclear Medicine Product Introduction
1.2 Market by Type
1.2.1 Global Radiopharmaceuticals in Nuclear Medicine Market Size Growth Rate by Type, 2017 VS 2021 VS 2028
1.2.2 Diagnostic Radiopharmaceuticals
1.2.3 Therapy Radiopharmaceuticals
1.2.4 Enriched Stable Isotopes
1.3 Market by Application
1.3.1 Global Radiopharmaceuticals in Nuclear Medicine Market Size Growth Rate by Application, 2017 VS 2021 VS 2028
1.3.2 Diagnostic Application
1.3.3 Therapeutic Application
1.3.4 Research
1.3.5 Pharmaceutical
1.3.6 Other
1.4 Study Objectives
1.5 Years Considered
2 Executive Summary
2.1 Global Radiopharmaceuticals in Nuclear Medicine Sales Estimates and Forecasts 2017-2028
2.2 Global Radiopharmaceuticals in Nuclear Medicine Revenue Estimates and Forecasts 2017-2028
2.3 Global Radiopharmaceuticals in Nuclear Medicine Revenue by Region: 2017 VS 2021 VS 2028
2.4 Global Radiopharmaceuticals in Nuclear Medicine Sales by Region
2.4.1 Global Radiopharmaceuticals in Nuclear Medicine Sales by Region (2017-2022)
2.4.2 Global Sales Radiopharmaceuticals in Nuclear Medicine by Region (2023-2028)
2.5 Global Radiopharmaceuticals in Nuclear Medicine Revenue by Region
2.5.1 Global Radiopharmaceuticals in Nuclear Medicine Revenue by Region (2017-2022)
2.5.2 Global Radiopharmaceuticals in Nuclear Medicine Revenue by Region (2023-2028)
2.6 North America
2.7 Europe
2.8 Asia-Pacific
2.9 Latin America
2.10 Middle East & Africa
3 Competition by Manufacturers
3.1 Global Radiopharmaceuticals in Nuclear Medicine Sales by Manufacturers
3.1.1 Global Top Radiopharmaceuticals in Nuclear Medicine Manufacturers by Sales (2017-2022)
3.1.2 Global Radiopharmaceuticals in Nuclear Medicine Sales Market Share by Manufacturers (2017-2022)
3.1.3 Global Top 10 and Top 5 Largest Manufacturers of Radiopharmaceuticals in Nuclear Medicine in 2021
3.2 Global Radiopharmaceuticals in Nuclear Medicine Revenue by Manufacturers
3.2.1 Global Radiopharmaceuticals in Nuclear Medicine Revenue by Manufacturers (2017-2022)
3.2.2 Global Radiopharmaceuticals in Nuclear Medicine Revenue Market Share by Manufacturers (2017-2022)
3.2.3 Global Top 10 and Top 5 Companies by Radiopharmaceuticals in Nuclear Medicine Revenue in 2021
3.3 Global Radiopharmaceuticals in Nuclear Medicine Sales Price by Manufacturers (2017-2022)
3.4 Analysis of Competitive Landscape
3.4.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Radiopharmaceuticals in Nuclear Medicine Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.4.3 Global Radiopharmaceuticals in Nuclear Medicine Manufacturers Geographical Distribution
3.5 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type
4.1 Global Radiopharmaceuticals in Nuclear Medicine Sales by Type
4.1.1 Global Radiopharmaceuticals in Nuclear Medicine Historical Sales by Type (2017-2022)
4.1.2 Global Radiopharmaceuticals in Nuclear Medicine Forecasted Sales by Type (2023-2028)
4.1.3 Global Radiopharmaceuticals in Nuclear Medicine Sales Market Share by Type (2017-2028)
4.2 Global Radiopharmaceuticals in Nuclear Medicine Revenue by Type
4.2.1 Global Radiopharmaceuticals in Nuclear Medicine Historical Revenue by Type (2017-2022)
4.2.2 Global Radiopharmaceuticals in Nuclear Medicine Forecasted Revenue by Type (2023-2028)
4.2.3 Global Radiopharmaceuticals in Nuclear Medicine Revenue Market Share by Type (2017-2028)
4.3 Global Radiopharmaceuticals in Nuclear Medicine Price by Type
4.3.1 Global Radiopharmaceuticals in Nuclear Medicine Price by Type (2017-2022)
4.3.2 Global Radiopharmaceuticals in Nuclear Medicine Price Forecast by Type (2023-2028)
5 Market Size by Application
5.1 Global Radiopharmaceuticals in Nuclear Medicine Sales by Application
5.1.1 Global Radiopharmaceuticals in Nuclear Medicine Historical Sales by Application (2017-2022)
5.1.2 Global Radiopharmaceuticals in Nuclear Medicine Forecasted Sales by Application (2023-2028)
5.1.3 Global Radiopharmaceuticals in Nuclear Medicine Sales Market Share by Application (2017-2028)
5.2 Global Radiopharmaceuticals in Nuclear Medicine Revenue by Application
5.2.1 Global Radiopharmaceuticals in Nuclear Medicine Historical Revenue by Application (2017-2022)
5.2.2 Global Radiopharmaceuticals in Nuclear Medicine Forecasted Revenue by Application (2023-2028)
5.2.3 Global Radiopharmaceuticals in Nuclear Medicine Revenue Market Share by Application (2017-2028)
5.3 Global Radiopharmaceuticals in Nuclear Medicine Price by Application
5.3.1 Global Radiopharmaceuticals in Nuclear Medicine Price by Application (2017-2022)
5.3.2 Global Radiopharmaceuticals in Nuclear Medicine Price Forecast by Application (2023-2028)
6 North America
6.1 North America Radiopharmaceuticals in Nuclear Medicine Market Size by Type
6.1.1 North America Radiopharmaceuticals in Nuclear Medicine Sales by Type (2017-2028)
6.1.2 North America Radiopharmaceuticals in Nuclear Medicine Revenue by Type (2017-2028)
6.2 North America Radiopharmaceuticals in Nuclear Medicine Market Size by Application
6.2.1 North America Radiopharmaceuticals in Nuclear Medicine Sales by Application (2017-2028)
6.2.2 North America Radiopharmaceuticals in Nuclear Medicine Revenue by Application (2017-2028)
6.3 North America Radiopharmaceuticals in Nuclear Medicine Market Size by Country
6.3.1 North America Radiopharmaceuticals in Nuclear Medicine Sales by Country (2017-2028)
6.3.2 North America Radiopharmaceuticals in Nuclear Medicine Revenue by Country (2017-2028)
6.3.3 U.S.
6.3.4 Canada
7 Europe
7.1 Europe Radiopharmaceuticals in Nuclear Medicine Market Size by Type
7.1.1 Europe Radiopharmaceuticals in Nuclear Medicine Sales by Type (2017-2028)
7.1.2 Europe Radiopharmaceuticals in Nuclear Medicine Revenue by Type (2017-2028)
7.2 Europe Radiopharmaceuticals in Nuclear Medicine Market Size by Application
7.2.1 Europe Radiopharmaceuticals in Nuclear Medicine Sales by Application (2017-2028)
7.2.2 Europe Radiopharmaceuticals in Nuclear Medicine Revenue by Application (2017-2028)
7.3 Europe Radiopharmaceuticals in Nuclear Medicine Market Size by Country
7.3.1 Europe Radiopharmaceuticals in Nuclear Medicine Sales by Country (2017-2028)
7.3.2 Europe Radiopharmaceuticals in Nuclear Medicine Revenue by Country (2017-2028)
7.3.3 Germany
7.3.4 France
7.3.5 U.K.
7.3.6 Italy
7.3.7 Russia
8 Asia Pacific
8.1 Asia Pacific Radiopharmaceuticals in Nuclear Medicine Market Size by Type
8.1.1 Asia Pacific Radiopharmaceuticals in Nuclear Medicine Sales by Type (2017-2028)
8.1.2 Asia Pacific Radiopharmaceuticals in Nuclear Medicine Revenue by Type (2017-2028)
8.2 Asia Pacific Radiopharmaceuticals in Nuclear Medicine Market Size by Application
8.2.1 Asia Pacific Radiopharmaceuticals in Nuclear Medicine Sales by Application (2017-2028)
8.2.2 Asia Pacific Radiopharmaceuticals in Nuclear Medicine Revenue by Application (2017-2028)
8.3 Asia Pacific Radiopharmaceuticals in Nuclear Medicine Market Size by Region
8.3.1 Asia Pacific Radiopharmaceuticals in Nuclear Medicine Sales by Region (2017-2028)
8.3.2 Asia Pacific Radiopharmaceuticals in Nuclear Medicine Revenue by Region (2017-2028)
8.3.3 China
8.3.4 Japan
8.3.5 South Korea
8.3.6 India
8.3.7 Australia
8.3.8 Taiwan
8.3.9 Indonesia
8.3.10 Thailand
8.3.11 Malaysia
8.3.12 Philippines
9 Latin America
9.1 Latin America Radiopharmaceuticals in Nuclear Medicine Market Size by Type
9.1.1 Latin America Radiopharmaceuticals in Nuclear Medicine Sales by Type (2017-2028)
9.1.2 Latin America Radiopharmaceuticals in Nuclear Medicine Revenue by Type (2017-2028)
9.2 Latin America Radiopharmaceuticals in Nuclear Medicine Market Size by Application
9.2.1 Latin America Radiopharmaceuticals in Nuclear Medicine Sales by Application (2017-2028)
9.2.2 Latin America Radiopharmaceuticals in Nuclear Medicine Revenue by Application (2017-2028)
9.3 Latin America Radiopharmaceuticals in Nuclear Medicine Market Size by Country
9.3.1 Latin America Radiopharmaceuticals in Nuclear Medicine Sales by Country (2017-2028)
9.3.2 Latin America Radiopharmaceuticals in Nuclear Medicine Revenue by Country (2017-2028)
9.3.3 Mexico
9.3.4 Brazil
9.3.5 Argentina
10 Middle East and Africa
10.1 Middle East and Africa Radiopharmaceuticals in Nuclear Medicine Market Size by Type
10.1.1 Middle East and Africa Radiopharmaceuticals in Nuclear Medicine Sales by Type (2017-2028)
10.1.2 Middle East and Africa Radiopharmaceuticals in Nuclear Medicine Revenue by Type (2017-2028)
10.2 Middle East and Africa Radiopharmaceuticals in Nuclear Medicine Market Size by Application
10.2.1 Middle East and Africa Radiopharmaceuticals in Nuclear Medicine Sales by Application (2017-2028)
10.2.2 Middle East and Africa Radiopharmaceuticals in Nuclear Medicine Revenue by Application (2017-2028)
10.3 Middle East and Africa Radiopharmaceuticals in Nuclear Medicine Market Size by Country
10.3.1 Middle East and Africa Radiopharmaceuticals in Nuclear Medicine Sales by Country (2017-2028)
10.3.2 Middle East and Africa Radiopharmaceuticals in Nuclear Medicine Revenue by Country (2017-2028)
10.3.3 Turkey
10.3.4 Saudi Arabia
11 Company Profiles
11.1 Bracco Imaging S.P.A.
11.1.1 Bracco Imaging S.P.A. Corporation Information
11.1.2 Bracco Imaging S.P.A. Overview
11.1.3 Bracco Imaging S.P.A. Radiopharmaceuticals in Nuclear Medicine Sales, Price, Revenue and Gross Margin (2017-2022)
11.1.4 Bracco Imaging S.P.A. Radiopharmaceuticals in Nuclear Medicine Product Model Numbers, Pictures, Descriptions and Specifications
11.1.5 Bracco Imaging S.P.A. Recent Developments
11.2 Cambridge Isotope Laboratories, Inc.
11.2.1 Cambridge Isotope Laboratories, Inc. Corporation Information
11.2.2 Cambridge Isotope Laboratories, Inc. Overview
11.2.3 Cambridge Isotope Laboratories, Inc. Radiopharmaceuticals in Nuclear Medicine Sales, Price, Revenue and Gross Margin (2017-2022)
11.2.4 Cambridge Isotope Laboratories, Inc. Radiopharmaceuticals in Nuclear Medicine Product Model Numbers, Pictures, Descriptions and Specifications
11.2.5 Cambridge Isotope Laboratories, Inc. Recent Developments
11.3 Cardinal Health, Inc.
11.3.1 Cardinal Health, Inc. Corporation Information
11.3.2 Cardinal Health, Inc. Overview
11.3.3 Cardinal Health, Inc. Radiopharmaceuticals in Nuclear Medicine Sales, Price, Revenue and Gross Margin (2017-2022)
11.3.4 Cardinal Health, Inc. Radiopharmaceuticals in Nuclear Medicine Product Model Numbers, Pictures, Descriptions and Specifications
11.3.5 Cardinal Health, Inc. Recent Developments
11.4 Covidien, Plc
11.4.1 Covidien, Plc Corporation Information
11.4.2 Covidien, Plc Overview
11.4.3 Covidien, Plc Radiopharmaceuticals in Nuclear Medicine Sales, Price, Revenue and Gross Margin (2017-2022)
11.4.4 Covidien, Plc Radiopharmaceuticals in Nuclear Medicine Product Model Numbers, Pictures, Descriptions and Specifications
11.4.5 Covidien, Plc Recent Developments
11.5 Eczacibasi-Monrol
11.5.1 Eczacibasi-Monrol Corporation Information
11.5.2 Eczacibasi-Monrol Overview
11.5.3 Eczacibasi-Monrol Radiopharmaceuticals in Nuclear Medicine Sales, Price, Revenue and Gross Margin (2017-2022)
11.5.4 Eczacibasi-Monrol Radiopharmaceuticals in Nuclear Medicine Product Model Numbers, Pictures, Descriptions and Specifications
11.5.5 Eczacibasi-Monrol Recent Developments
11.6 Fujifilm Holdings Corporation
11.6.1 Fujifilm Holdings Corporation Corporation Information
11.6.2 Fujifilm Holdings Corporation Overview
11.6.3 Fujifilm Holdings Corporation Radiopharmaceuticals in Nuclear Medicine Sales, Price, Revenue and Gross Margin (2017-2022)
11.6.4 Fujifilm Holdings Corporation Radiopharmaceuticals in Nuclear Medicine Product Model Numbers, Pictures, Descriptions and Specifications
11.6.5 Fujifilm Holdings Corporation Recent Developments
11.7 GE Healthcare (Subsidiary Of General Electric Company)
11.7.1 GE Healthcare (Subsidiary Of General Electric Company) Corporation Information
11.7.2 GE Healthcare (Subsidiary Of General Electric Company) Overview
11.7.3 GE Healthcare (Subsidiary Of General Electric Company) Radiopharmaceuticals in Nuclear Medicine Sales, Price, Revenue and Gross Margin (2017-2022)
11.7.4 GE Healthcare (Subsidiary Of General Electric Company) Radiopharmaceuticals in Nuclear Medicine Product Model Numbers, Pictures, Descriptions and Specifications
11.7.5 GE Healthcare (Subsidiary Of General Electric Company) Recent Developments
11.8 IBA Group
11.8.1 IBA Group Corporation Information
11.8.2 IBA Group Overview
11.8.3 IBA Group Radiopharmaceuticals in Nuclear Medicine Sales, Price, Revenue and Gross Margin (2017-2022)
11.8.4 IBA Group Radiopharmaceuticals in Nuclear Medicine Product Model Numbers, Pictures, Descriptions and Specifications
11.8.5 IBA Group Recent Developments
11.9 Isotec, Inc. (Sigma-Aldrich)
11.9.1 Isotec, Inc. (Sigma-Aldrich) Corporation Information
11.9.2 Isotec, Inc. (Sigma-Aldrich) Overview
11.9.3 Isotec, Inc. (Sigma-Aldrich) Radiopharmaceuticals in Nuclear Medicine Sales, Price, Revenue and Gross Margin (2017-2022)
11.9.4 Isotec, Inc. (Sigma-Aldrich) Radiopharmaceuticals in Nuclear Medicine Product Model Numbers, Pictures, Descriptions and Specifications
11.9.5 Isotec, Inc. (Sigma-Aldrich) Recent Developments
11.10 Lantheus Medical Imaging, Inc.
11.10.1 Lantheus Medical Imaging, Inc. Corporation Information
11.10.2 Lantheus Medical Imaging, Inc. Overview
11.10.3 Lantheus Medical Imaging, Inc. Radiopharmaceuticals in Nuclear Medicine Sales, Price, Revenue and Gross Margin (2017-2022)
11.10.4 Lantheus Medical Imaging, Inc. Radiopharmaceuticals in Nuclear Medicine Product Model Numbers, Pictures, Descriptions and Specifications
11.10.5 Lantheus Medical Imaging, Inc. Recent Developments
11.11 Nordion, Inc.
11.11.1 Nordion, Inc. Corporation Information
11.11.2 Nordion, Inc. Overview
11.11.3 Nordion, Inc. Radiopharmaceuticals in Nuclear Medicine Sales, Price, Revenue and Gross Margin (2017-2022)
11.11.4 Nordion, Inc. Radiopharmaceuticals in Nuclear Medicine Product Model Numbers, Pictures, Descriptions and Specifications
11.11.5 Nordion, Inc. Recent Developments
11.12 Ntp Radioisotopes (Pty), Ltd.
11.12.1 Ntp Radioisotopes (Pty), Ltd. Corporation Information
11.12.2 Ntp Radioisotopes (Pty), Ltd. Overview
11.12.3 Ntp Radioisotopes (Pty), Ltd. Radiopharmaceuticals in Nuclear Medicine Sales, Price, Revenue and Gross Margin (2017-2022)
11.12.4 Ntp Radioisotopes (Pty), Ltd. Radiopharmaceuticals in Nuclear Medicine Product Model Numbers, Pictures, Descriptions and Specifications
11.12.5 Ntp Radioisotopes (Pty), Ltd. Recent Developments
11.13 Siemens Healthcare (Subsidiary Of Siemens AG)
11.13.1 Siemens Healthcare (Subsidiary Of Siemens AG) Corporation Information
11.13.2 Siemens Healthcare (Subsidiary Of Siemens AG) Overview
11.13.3 Siemens Healthcare (Subsidiary Of Siemens AG) Radiopharmaceuticals in Nuclear Medicine Sales, Price, Revenue and Gross Margin (2017-2022)
11.13.4 Siemens Healthcare (Subsidiary Of Siemens AG) Radiopharmaceuticals in Nuclear Medicine Product Model Numbers, Pictures, Descriptions and Specifications
11.13.5 Siemens Healthcare (Subsidiary Of Siemens AG) Recent Developments
11.14 Taiyo Nippon Sanso Corporation
11.14.1 Taiyo Nippon Sanso Corporation Corporation Information
11.14.2 Taiyo Nippon Sanso Corporation Overview
11.14.3 Taiyo Nippon Sanso Corporation Radiopharmaceuticals in Nuclear Medicine Sales, Price, Revenue and Gross Margin (2017-2022)
11.14.4 Taiyo Nippon Sanso Corporation Radiopharmaceuticals in Nuclear Medicine Product Model Numbers, Pictures, Descriptions and Specifications
11.14.5 Taiyo Nippon Sanso Corporation Recent Developments
11.15 Urenco Limited
11.15.1 Urenco Limited Corporation Information
11.15.2 Urenco Limited Overview
11.15.3 Urenco Limited Radiopharmaceuticals in Nuclear Medicine Sales, Price, Revenue and Gross Margin (2017-2022)
11.15.4 Urenco Limited Radiopharmaceuticals in Nuclear Medicine Product Model Numbers, Pictures, Descriptions and Specifications
11.15.5 Urenco Limited Recent Developments
11.16 Rotem Industries, Ltd., Inc.
11.16.1 Rotem Industries, Ltd., Inc. Corporation Information
11.16.2 Rotem Industries, Ltd., Inc. Overview
11.16.3 Rotem Industries, Ltd., Inc. Radiopharmaceuticals in Nuclear Medicine Sales, Price, Revenue and Gross Margin (2017-2022)
11.16.4 Rotem Industries, Ltd., Inc. Radiopharmaceuticals in Nuclear Medicine Product Model Numbers, Pictures, Descriptions and Specifications
11.16.5 Rotem Industries, Ltd., Inc. Recent Developments
11.17 Australian Nuclear Association And Technology Organization (ANSTO)
11.17.1 Australian Nuclear Association And Technology Organization (ANSTO) Corporation Information
11.17.2 Australian Nuclear Association And Technology Organization (ANSTO) Overview
11.17.3 Australian Nuclear Association And Technology Organization (ANSTO) Radiopharmaceuticals in Nuclear Medicine Sales, Price, Revenue and Gross Margin (2017-2022)
11.17.4 Australian Nuclear Association And Technology Organization (ANSTO) Radiopharmaceuticals in Nuclear Medicine Product Model Numbers, Pictures, Descriptions and Specifications
11.17.5 Australian Nuclear Association And Technology Organization (ANSTO) Recent Developments
11.18 Board of Radiation And Isotope Technology (BRIT)
11.18.1 Board of Radiation And Isotope Technology (BRIT) Corporation Information
11.18.2 Board of Radiation And Isotope Technology (BRIT) Overview
11.18.3 Board of Radiation And Isotope Technology (BRIT) Radiopharmaceuticals in Nuclear Medicine Sales, Price, Revenue and Gross Margin (2017-2022)
11.18.4 Board of Radiation And Isotope Technology (BRIT) Radiopharmaceuticals in Nuclear Medicine Product Model Numbers, Pictures, Descriptions and Specifications
11.18.5 Board of Radiation And Isotope Technology (BRIT) Recent Developments
11.19 Institute of Atomic Energy Polatom Radioisotope Centre
11.19.1 Institute of Atomic Energy Polatom Radioisotope Centre Corporation Information
11.19.2 Institute of Atomic Energy Polatom Radioisotope Centre Overview
11.19.3 Institute of Atomic Energy Polatom Radioisotope Centre Radiopharmaceuticals in Nuclear Medicine Sales, Price, Revenue and Gross Margin (2017-2022)
11.19.4 Institute of Atomic Energy Polatom Radioisotope Centre Radiopharmaceuticals in Nuclear Medicine Product Model Numbers, Pictures, Descriptions and Specifications
11.19.5 Institute of Atomic Energy Polatom Radioisotope Centre Recent Developments
11.20 Institute of Isotopes Co., Ltd.
11.20.1 Institute of Isotopes Co., Ltd. Corporation Information
11.20.2 Institute of Isotopes Co., Ltd. Overview
11.20.3 Institute of Isotopes Co., Ltd. Radiopharmaceuticals in Nuclear Medicine Sales, Price, Revenue and Gross Margin (2017-2022)
11.20.4 Institute of Isotopes Co., Ltd. Radiopharmaceuticals in Nuclear Medicine Product Model Numbers, Pictures, Descriptions and Specifications
11.20.5 Institute of Isotopes Co., Ltd. Recent Developments
11.21 Institute Of Radioelement (IRE)
11.21.1 Institute Of Radioelement (IRE) Corporation Information
11.21.2 Institute Of Radioelement (IRE) Overview
11.21.3 Institute Of Radioelement (IRE) Radiopharmaceuticals in Nuclear Medicine Sales, Price, Revenue and Gross Margin (2017-2022)
11.21.4 Institute Of Radioelement (IRE) Radiopharmaceuticals in Nuclear Medicine Product Model Numbers, Pictures, Descriptions and Specifications
11.21.5 Institute Of Radioelement (IRE) Recent Developments
12 Industry Chain and Sales Channels Analysis
12.1 Radiopharmaceuticals in Nuclear Medicine Industry Chain Analysis
12.2 Radiopharmaceuticals in Nuclear Medicine Key Raw Materials
12.2.1 Key Raw Materials
12.2.2 Raw Materials Key Suppliers
12.3 Radiopharmaceuticals in Nuclear Medicine Production Mode & Process
12.4 Radiopharmaceuticals in Nuclear Medicine Sales and Marketing
12.4.1 Radiopharmaceuticals in Nuclear Medicine Sales Channels
12.4.2 Radiopharmaceuticals in Nuclear Medicine Distributors
12.5 Radiopharmaceuticals in Nuclear Medicine Customers
13 Market Drivers, Opportunities, Challenges and Risks Factors Analysis
13.1 Radiopharmaceuticals in Nuclear Medicine Industry Trends
13.2 Radiopharmaceuticals in Nuclear Medicine Market Drivers
13.3 Radiopharmaceuticals in Nuclear Medicine Market Challenges
13.4 Radiopharmaceuticals in Nuclear Medicine Market Restraints
14 Key Findings in The Global Radiopharmaceuticals in Nuclear Medicine Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Author Details
15.3 Disclaimer